Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece

Introduction: Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD gene, is the rate-limiting enzyme responsible for fluoropyrimidine (FP) catabolism. DPYD gene variants seriously affect DPD activity and are well validated predictors of FP-associated toxicity. DPYD variants rs3918290, rs55886062,...

Full description

Bibliographic Details
Main Authors: Georgia Ragia, Anthi Maslarinou, Natalia Atzemian, Eirini Biziota, Triantafyllia Koukaki, Charalampia Ioannou, Ioanna Balgkouranidou, George Kolios, Stylianos Kakolyris, Nikolaos Xenidis, Kyriakos Amarantidis, Vangelis G. Manolopoulos
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Pharmacology
Subjects:
DPYD
pharmacogenomics
fluoropyrimidines
5-fluοrouracil
capecitabine
clinical implementation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1248898/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1248898/full

Similar Items